Clinical Trial Update: A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A phase 2 multi-center study evaluating lapatinib in patients with trastuzumab-refractory metastatic HER2-positive breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: HER2 Positive Breast Cancer | Phase 2 | Status: COMPLETED